Lutetium (177Lu) chloride
Lutetium (177Lu) chloride, sold under the brand name Lumark among others, is a radioactive compound used for radiolabeling other medicines.[1][2]
Clinical data | |
---|---|
Trade names | Lumark, EndolucinBeta |
AHFS/Drugs.com | UK Drug Information |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | Cl3Lu |
Molar mass | 281.32 g·mol−1 |
3D model (JSmol) | |
| |
|
The most common side effects are anaemia (low red blood cell counts), thrombocytopenia (low blood platelet counts), leucopenia (low white blood cell counts), lymphopenia (low levels of lymphocytes, a particular type of white blood cell), nausea (feeling sick), vomiting and mild and temporary hair loss.[1]
Medical uses
Lutetium (177Lu) chloride is a radiopharmaceutical precursor, and it is not intended for direct use in patients.[1] It is to be used only for the radiolabeling of carrier molecules that have been specifically developed and authorised for radiolabeling with Lutetium (177Lu) chloride.[1]
Contraindications
Medicines radiolabeled with lutetium (177Lu) chloride must not be used in women unless pregnancy has been ruled out.[1]
History
Lutetium (177Lu) chloride was approved for use in the European Union in June 2015.[1]
See also
References
- "Lumark EPAR". European Medicines Agency. 17 September 2018. Retrieved 7 May 2020.
This article incorporates text from this source, which is in the public domain. - "EndolucinBeta EPAR". European Medicines Agency (EMA). Retrieved 7 May 2020.
This article incorporates text from this source, which is in the public domain.
External links
- "Lutetium chloride Lu-177". Drug Information Portal. U.S. National Library of Medicine.